GKOS
GLAUKOS Corp
+0.59 (+0.36%)164.06USD162K成交股數9.7B市值–本益比(近四季)15.8股價營收比+49.5%營收年增(近四季)2026-10-28下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 186M+74% | 151M+43% | 134M+38% | 124M+30% | 107M+25% | 105M+35% | 96.7M+20% | 95.7M+29% | 85.6M | 78.0M | 80.4M | 73.9M |
| 營業成本 | 34.0M | 33.3M | 28.8M | 26.9M | 24.3M | 28.6M | 22.6M | 22.6M | 20.3M | 18.5M | 20.1M | 18.1M |
| 毛利 | 152M+84% | 117M+53% | 105M+41% | 97.2M+33% | 82.3M+26% | 76.9M+29% | 74.1M+23% | 73.1M+31% | 65.4M | 59.5M | 60.3M | 55.8M |
| 毛利率 | 81.7% | 77.9% | 78.4% | 78.3% | 77.2% | 72.9% | 76.6% | 76.4% | 76.3% | 76.3% | 75.0% | 75.5% |
| 研發費用 | 51.3M | 44.1M | 38.1M | 36.5M | 32.4M | 36.5M | 34.7M | 34.4M | 30.7M | 33.3M | 33.2M | 35.2M |
| 銷售管理費用 | 116M | 92.9M | 83.0M | 83.4M | 70.7M | 69.0M | 64.0M | 66.2M | 62.0M | 54.2M | 53.1M | 53.7M |
| 營業利益 | −17.3M-16% | −19.9M-31% | −16.4M-34% | −22.7M-24% | −20.7M-47% | −28.7M+2% | −24.7M-15% | −30.0M-9% | −39.1M | −28.0M | −29.1M | −33.0M |
| 營業利益率 | -9.3% | -13.2% | -12.3% | -18.3% | -19.4% | -27.2% | -25.5% | -31.3% | -45.6% | -35.9% | -36.2% | -44.6% |
| 稅後淨利 | −18.4M+1% | −19.8M-41% | −16.2M-24% | −19.7M-61% | −18.1M-56% | −33.6M+10% | −21.4M-35% | −50.5M+46% | −40.8M | −30.4M | −32.8M | −34.6M |
| 淨利率 | -9.9% | -13.1% | -12.2% | -15.8% | -17.0% | -31.8% | -22.1% | -52.8% | -47.7% | -39.0% | -40.8% | -46.9% |
| 稀釋 EPS | -0.31-3% | -0.34-39% | -0.28-28% | -0.34-66% | -0.32-61% | -0.56-11% | -0.39-43% | -1.00+39% | -0.82 | -0.63 | -0.68 | -0.72 |
| 稀釋股數 | 58.8M | 58.0M | 57.4M | 57.2M | 56.6M | 52.8M | 55.0M | 50.7M | 49.6M | 48.7M | 48.3M | 47.9M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 114M | 104M | 98.2M | 101M | 114M | 170M | 100M | 68.1M | 42.5M | 109M | 94.8M | 76.4M |
| 應收帳款 | 139M | 120M | 98.7M | 83.0M | 71.5M | 60.7M | 56.4M | 51.2M | 46.5M | 39.3M | 39.3M | 37.9M |
| 存貨 | 59.3M | 62.4M | 63.9M | 64.6M | 59.5M | 57.7M | 59.9M | 56.5M | 50.2M | 39.8M | 39.4M | 40.5M |
| 總資產 | 921M | 893M | 999M | 987M | 966M | 975M | 927M | 920M | 933M | 949M | 957M | 973M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 238M | 222M | 230M | 222M | 202M | 208M | 258M | 255M | 483M | 471M | 468M | 464M |
| 股東權益 | 682M | 671M | 770M | 765M | 764M | 767M | 669M | 665M | 451M | 478M | 489M | 509M |
| 負債比 | 25.9% | 24.9% | 23.0% | 22.5% | 20.9% | 21.3% | 27.8% | 27.7% | 51.7% | 49.6% | 48.9% | 47.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −12.5M | – | – | −18.5M-45% | – | – | – | −33.9M | – | – | −30.8M |
| 資本支出 | – | 4.0M | – | – | 1.9M | – | – | – | 968K | – | – | 6.9M |
| 自由現金流 | – | −16.5M | – | – | −20.5M-41% | – | – | – | −34.8M | – | – | −37.7M |
| 折舊攤銷 | – | 11.8M | – | – | 8.2M | – | – | – | 8.9M | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -10.9% | – | – | -19.2% | – | – | – | -40.7% | – | – | -51.0% |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 507M
| Development And Commercialization Of Ophthalmic Therapies | 507M | 100.0% | +32.3% |
|---|
地區2025 年度 · 507M
| 美國 | 375M | 73.9% | +38.9% |
|---|---|---|---|
| 美國以外 | 132M | 26.1% | +16.8% |
產品／服務2025 年度 · 507M
| Glaucoma | 421M | 83.0% | +38.8% |
|---|---|---|---|
| Corneal Health | 86.4M | 17.0% | +7.7% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 507M | +32.3% | −188M | -37.0% | -3.28 | −22.5M |
| FY2024 | 383M | +21.9% | −146M | -38.2% | -2.77 | −67.6M |
| FY2023 | 315M | +11.3% | −135M | -42.8% | -2.78 | −78.0M |
| FY2022 | 283M | -3.8% | −99.2M | -35.1% | -2.09 | −63.3M |
| FY2021 | 294M | +30.7% | −49.6M | -16.9% | -1.07 | −23.1M |
| FY2020 | 225M | -5.1% | −120M | -53.5% | -2.70 | −29.9M |
| FY2019 | 237M | +30.7% | 15.4M | 6.5% | 0.37 | −5.1M |
| FY2018 | 181M | – | −13.0M | -7.1% | -0.37 | 8.5M |